Skip to content
Medical Health Aged Care

Population DNA screening for multiple diseases would save lives and be cost effective: study

Monash University 3 mins read

Offering population-wide genetic screening for risk of deadly but preventable diseases to young adults would save lives and be cost-effective in Australia, a Monash University-led study has found.

The study used health economic evaluation to model combined DNA screening for all adults in Australia aged 18-40 years, to identify risk of three different genetic conditions:

  • hereditary breast and ovarian cancer (caused by the BRCA1 and BRCA2 genes)
  • a type of genetic high cholesterol called familial hypercholesterolemia, and 
  • Lynch syndrome, a genetic condition that increases the risk of colorectal and other cancers.

All three conditions can be treated or prevented if detected early. Around one in 75 people are at  high genetic risk of one of these conditions, but most are unaware and therefore not accessing available life-saving interventions. 

Published in The Lancet’s eClinicalMedicine journal, the modelling study used previous Australian and international evidence to extrapolate whether widespread preventive DNA screening for multiple diseases together would be cost-effective in the Australian public healthcare system, compared with the status quo of targeted clinical criteria-based testing.

The study found that offering population-level preventive testing to all 18-40-year-olds would be cost-effective in Australia, compared with the current practice of limited genetic testing.   

Co-first author Associate Professor Paul Lacaze, from the Monash University School of Public Health and Preventive Medicine, said: “This modelling forms a critical pillar of evidence to support the development of a new DNA-based population screening program in Australia for cancer and heart disease risk. 

“We can now say with confidence, based on our rigorous modelling analysis, that offering population-wide preventive DNA screening to young adults in Australia would not only save lives but also be cost-effective. 

“Offering this type of DNA screening would finally maximize the preventive potential of genomics, and deliver many public health benefits to the Australian population.” 

Over the simulated model of 8.3 million adults’ lifetime to age 80, assuming 50 per cent uptake of DNA screening, an estimated 4047 deaths could be averted. It would also prevent 2612 cancers (1,140 breast, 950 ovarian, 451 colorectal and 71 endometrial) and 542 non-fatal coronary heart disease (CHD) events. 

This is equal to preventing 63 cancers, 31 CHD cases and 97 deaths averted per 100,000 people offered DNA screening, versus current practice. 

At $200 per test, a total government investment of $832 million would be required to screen 50 per cent of the model population. This investment would also cover $539 per high-risk person identified, for clinical confirmation testing and genetic counselling.

The study found the initial cost would be well worth it, given the overall benefit to society through early detection and prevention, with an incremental cost-effectiveness ratio (ICER) of AU$23,926 per quality-adjusted life-year (QALY) gained, as a result of the population genomic screening. 

Senior author Professor Zanfina Ademi, who leads Monash University’s Health Economics and Policy Evaluation Research Group in the Faculty of Pharmacy and Pharmaceutical Sciences, said that combined population genomic screening for high-risk conditions in the young adult population may be cost-effective from the public healthcare perspective, compared to the current status-quo.

Professor Ademi said this was based on the willingness-to-pay threshold of AU$50,000 - the amount the healthcare system is willing to spend per quality-adjusted life year gained.

“If you looked at it from a societal perspective, with potential healthcare costs and costs of lost work productivity considered, combined genomic screening would save lives and money compared to the status quo,” she said. 

“This societal perspective is often considered in cost-effectiveness calculations conducted overseas. 

“This further emphasises the importance of allocating scarce resources to preventive health so that society gains overall in the long term from combined genomic screening, rather than testing or screening for single conditions individually, which is current practice.” 

Co-first author Dr Clara Marquina, a Faculty of Pharmacy and Pharmaceutical Sciences, Adjunct Research Fellow, said  the state-of-art cost-effectiveness modelling techniques had provided evidence to inform policy and funding that could reduce the burden of disease. 

“Using best practice economic evaluation methods is key to informing successful policy, implementation and scaling up of healthcare technologies,” she said.

The modelling in this paper used the same genes and health conditions as a 2022 world-first DNA Screen pilot study, which has almost completed offering genomic screening to 10,000 young adults aged 18-40 in Australia. Results and outcomes of the pilot will be available in 2024.

“Australia has a proven ability to deliver population-based screening programs through our national public healthcare system,” said Associate Professor Lacaze, who is also chief investigator of the DNA Screen pilot study. 

“These successful programs are guided by our established National Population-Based Screening Framework. 

“Under these circumstances, the prospect of implementing a national DNA-based population screening program is feasible and exciting in Australia. Other matters, including psychosocial impacts, ethical and societal issues, and implementation challenges, also need consideration.

“We highlight the need for more public education and awareness of genomics; an appropriate informed-consent framework for population genomic screening to discuss potential benefits and harms, and the protection of high-risk individuals against genetic discrimination through new legislation in Australia.”

For media enquiries please contact:

Monash University
Cheryl Critchley - Communications Manager (medical)
T: +61 (0) 418 312 596

For more Monash media stories, visit our news and events site  
For general media enquiries please contact:
Monash Media
T: +61 (0) 3 9903 4840


More from this category

  • Environment, Medical Health Aged Care
  • 01/12/2023
  • 10:43
West Australian doctors peak bodies

WA doctors and health professionals call for the government to take urgent action on climate change and end fossil fuel expansion to protect health

On the 1st December, just prior to the COP28 Health Day on the 3rd December, representatives of the medical colleges for general practitioners (GPs), emergency doctors, rural and remote doctors, and surgeons, as well as other doctors and health professionals, gather at 8 am on the steps of Parliament House to call on the WA Government take urgent action on climate change and protect the health of Western Australians. Reiterating calls from medical colleges earlier this year in support of ending fossil fuel expansion and climate action, those gathered today ask the WA government to: End expansion of any new…

  • Medical Health Aged Care
  • 01/12/2023
  • 10:12
Australian Dental Industry Association

ADIA congratulates Senators of the Inquiry into the Provision of and Access to Dental Services in Australia

1 December The Australian Dental Industry Association congratulates the Senators of the Senate Select Committee Inquiry into the Provision of and Access to Dental…

  • Contains:
  • Medical Health Aged Care, Research Development
  • 01/12/2023
  • 09:17

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations. CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.